Nouveautés en oncologie: beaucoup de bruit pour rien? [New anticancer drugs: much ado about nothing?]

Détails

ID Serval
serval:BIB_A497A64A0AE1
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Nouveautés en oncologie: beaucoup de bruit pour rien? [New anticancer drugs: much ado about nothing?]
Périodique
Revue medicale suisse
Auteur(s)
Zimmermann S., Betticher D.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
09/04/2014
Peer-reviewed
Oui
Volume
10
Numéro
425
Pages
788,790-793
Langue
français
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Résumé
Multiple new cancer drugs have been marketed during the last decade, and among those many molecularly targeted agents. Their impact on clinical outcomes population-wide remains hard to measure. Are we merely seeing the development of expensive and toxic drugs that benefit a minority of patients, or are battles actually won in the war on cancer? Both epidemiologic trends and clinical trial data show that a patient's outcome today is significantly better than 10 or 20 years ago, in terms of cure rates and survival time for advanced disease.

Mots-clé
Antineoplastic Agents/adverse effects, Antineoplastic Agents/pharmacology, Antineoplastic Agents/therapeutic use, Clinical Trials as Topic, Drug Design, Humans, Molecular Targeted Therapy, Neoplasms/drug therapy, Neoplasms/pathology, Survival Rate, Treatment Outcome
Pubmed
Création de la notice
27/11/2017 19:27
Dernière modification de la notice
03/03/2018 20:14
Données d'usage